Related Experiment Video
Updated: Feb 14, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Managing Dyslipidemia in Type 2 Diabetes
Adam J Nelson1, Simon K Rochelau1, Stephen J Nicholls1
1South Australian Health and Medical Research Institute, PO Box 11060, Adelaide, SA 5001, Australia.
Insights
Individuals with diabetes face a higher risk of cardiovascular disease and atherosclerotic events. Effective management of diabetic dyslipidemia is crucial for mitigating these risks.
Area of Science:
- Endocrinology
- Cardiology
- Metabolic Disorders
Background:
- Cardiovascular disease (CVD) is a leading cause of death in diabetic patients.
- Diabetics have a twofold higher risk of atherosclerotic events despite risk reduction efforts.
- Insulin resistance in diabetes alters lipid profiles, complicating treatment.
Purpose of the Study:
- To review the background of diabetic dyslipidemia.
- To summarize current management strategies for diabetic dyslipidemia.
Main Methods:
- Literature review of studies on diabetes, dyslipidemia, and cardiovascular disease.
- Analysis of lipid profile changes associated with diabetes and insulin resistance.
- Overview of established and emerging treatment options.
Main Results:
- Diabetic dyslipidemia is characterized by specific lipid profile abnormalities.
- Aggressive management of traditional risk factors is essential.
- Current treatments aim to normalize lipid levels and reduce cardiovascular risk.
Conclusions:
- Diabetic dyslipidemia significantly increases cardiovascular morbidity and mortality.
- Comprehensive management of lipid disorders is a cornerstone of cardiovascular risk reduction in diabetes.
- Further research into optimal therapeutic approaches is warranted.
Abstract:
Cardiovascular disease is the most frequent cause of morbidity and mortality among individuals with diabetes and although there has been significant reduction in excess risk, these individuals remain at least twice as likely to sustain atherosclerotic events. Aggressive management of traditional factors, such as dyslipidemia, remains the cornerstone of risk mitigation. Diabetes and its associated insulin resistance generate qualitative and quantitative changes in lipid profile, which complicate effective treatment. This review summaries the background to diabetic dyslipidemia and provides a précis of the available management options.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Psychoneuroimmunology: Diabetes and Cancer
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H

